All In Biotech

Drug Trial Radar · NCT00933231

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Aug 17, 2009

Primary completion

May 11, 2015

Study completion Apr 3, 2018

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
Collaborators
Astellas Pharma Canada, Inc.
First posted
Jul 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.

Conditions

  • Kidney Transplantation

Interventions

  • tacrolimusDrug

    Standard dose, Oral

  • tacrolimusDrug

    Low dose, Oral

  • SimulectBiological

    IV

  • CellceptDrug

    Oral

  • CorticosteroidsDrug

    IV and Oral

  • RamiprilDrug

    Oral

  • IrbesartanDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with the Presence of Allograft Interstitial Fibrosis and Tubular Atrophy (IF/TA) as Assessed at a Central Pathology LabTime frame: up to 24 months
  2. Progression of IF/TA from Month 6 to Month 24Time frame: up to 24 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Site CA133 Foothills Medical Centre

    Calgary, Alberta, Canada

  • Site CA54 University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Site CA141 Health Sciences Centre

    Winnipeg, Manitoba, Canada

  • Site CA114 Capital District Health Authority- QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Site CA150 St. Joseph's Healthcare

    Hamilton, Ontario, Canada

  • Site CA27 London Health Sciences Centre

    London, Ontario, Canada

  • Site CA165 St. Michael's Hospital

    Toronto, Ontario, Canada

  • Site CA238 Hôpital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • Site CA172 Hôpital Notre-Dame du CHUM

    Montreal, Quebec, Canada

  • Site CA144 McGill University Health Centre

    Montreal, Quebec, Canada

  • Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec

    Québec, Quebec, Canada

  • Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont

    Sherbrooke, Quebec, Canada

  • Site CA142 St. Paul's Hospital

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.